Related Experiment Video
Updated: Jul 19, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Interventional treatments for hepatocellular carcinoma.
1Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China. YongsongGuan@yahoo.com
Hepatobiliary & Pancreatic Diseases International : HBPD INT
|November 7, 2006
Summary
Interventional treatments like local ablation and transarterial chemoembolization (TACE) offer options for hepatocellular carcinoma (HCC) patients ineligible for surgery. Further development of these methods is crucial for improving HCC prognosis.
Area of Science:
- Hepatology
- Interventional Oncology
- Medical Oncology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent malignancy globally.
- Surgical options like resection and transplantation are limited to 20% of HCC cases.
- Interventional management, including local ablation and TACE, is vital for non-surgically eligible patients.
Purpose of the Study:
- To review current interventional treatments for hepatocellular carcinoma (HCC).
- To discuss the efficacy and limitations of various local ablation techniques and TACE.
- To highlight emerging therapies and future directions in HCC management.
Main Methods:
- Comprehensive literature search of the PubMed database.
- Review and synthesis of research articles on HCC interventional therapies.
- Analysis of established and novel treatment modalities.
Main Results:
- Percutaneous ethanol injection (PEI) and radiofrequency ablation are effective for small HCC necrosis.
- Other local ablation methods include acetic acid injection, laser, and microwave; High Intensity Focus Ultrasound (HIFU) shows promise.
- Transarterial chemoembolization (TACE) improves survival; novel embolic agents and gene therapy (rAd-p53) are emerging.
Conclusions:
- Interventional procedures provide viable treatment options for surgically ineligible HCC patients.
- Each interventional method possesses distinct advantages and disadvantages.
- Continued innovation in ablative techniques and embolic agents is essential for enhancing HCC patient outcomes.
